According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Other research analysts also recently issued research reports about the company. Wedbush reissued an outperform rating on shares of Voyager Therapeutics in a research note on Wednesday. Morgan Stanley lowered their target price on Voyager Therapeutics from $28.00 to $26.00 and set an equal weight rating for the company in a research note on Friday, October 11th. ValuEngine downgraded Voyager Therapeutics from a hold rating to a sell rating in a research note on Friday. BidaskClub downgraded Voyager Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, August 27th. Finally, Cowen reaffirmed a buy rating on shares of Voyager Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $27.71.
Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Wednesday, November 6th. The company reported ($0.41) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.42. The firm had revenue of $20.43 million during the quarter, compared to the consensus estimate of $3.94 million. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. On average, research analysts expect that Voyager Therapeutics will post -1.95 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC acquired a new stake in Voyager Therapeutics during the 2nd quarter valued at approximately $27,000. Allianz Asset Management GmbH increased its position in Voyager Therapeutics by 16.5% during the 2nd quarter. Allianz Asset Management GmbH now owns 93,948 shares of the company’s stock valued at $2,054,000 after purchasing an additional 13,339 shares during the period. HM Payson & Co. acquired a new stake in Voyager Therapeutics during the 2nd quarter valued at approximately $63,000. Bailard Inc. acquired a new stake in Voyager Therapeutics during the 2nd quarter valued at approximately $1,116,000. Finally, JPMorgan Chase & Co. increased its position in Voyager Therapeutics by 28.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 326,643 shares of the company’s stock valued at $8,590,000 after purchasing an additional 71,451 shares during the period. 78.63% of the stock is owned by institutional investors.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Recommended Story: Trade War
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.